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Abstract
The aim of the study is to prepare aqueous dispersions of lipid nanoparticles – flurbiprofen solid
lipid nanoparticles (FLUSLN) and flurbiprofen nanostructured lipid carriers (FLUNLC) by hot
homogenization followed by sonication technique and then incorporated into the freshly prepared
hydrogels for transdermal delivery. They are characterized for particle size, for all the formulations,
more than 50% of the particles were below 300 nm after 90 days of storage at RT. DSC analyses
were performed to characterize the state of drug and lipid modification. Shape and surface
morphology were determined by TEM which revealed fairly spherical shape of the formulations.
Further they were evaluated for in vitro drug release characteristics, rheological behaviour,
pharmacokinetic and pharmacodynamic studies. The pharmacokinetics of flurbiprofen in rats
following application of SLN gel (A1) and NLC gel (B1) for 24 h were evaluated. The Cmax of the
B1 formulation was 38.67 ± 2.77 μg/ml, which was significantly higher than the A1 formulation
(Cmax = 21.79 ± 2.96 μg/ml). The Cmax and AUC of the B1 formulation were 1.8 and 2.5 times higher
than the A1 gel formulation respectively. The bioavailability of flurbiprofen with reference to oral
administration was found to increase by 4.4 times when gel formulations were applied. Anti-
inflammatory effect in the Carrageenan-induced paw edema in rat was significantly higher for B1
and A1 formulation than the orally administered flurbiprofen. Both the SLN and NLC dispersions
and gels enriched with SLN and NLC possessed a sustained drug release over period of 24 h but
the sustained effect was more pronounced with the SLN and NLC gel
Background
Drug delivery from colloidal systems such as solid lipid
nanoparticles (SLN) and nanostructured lipid carriers
(NLC) dispersed in a hydrogel appears to be unique when
compared to the delivery from traditional topical and der-
matological formulations. During the last decade, consid-
erable attention has been paid to the development of new
controlled delivery systems, in order to supply a long-term
drug release and, therefore, increase patient's therapeutic
compliance and acceptance. SLN and NLC are interesting
systems for the present purpose due to their solid matrix
which might avoid the burst release obtained in conven-
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tional topical formulations [1,2]. These lipid nanoparti-
cles differ from each other because in NLC a controlled
nanostructuring of the lipid matrix is performed due to
the mixture of solid and liquid lipids, in order to increase
drug-loading and prevent its expulsion. In addition, the
nanostructured lipid matrix gives more flexibility in mod-
ulation of drug release.
Solid lipid nanoparticles (SLN) and nanostructured lipid
carriers (NLC) are two main types of lipid nanoparticles.
SLN is a colloidal carrier system for controlled drug deliv-
ery, followed by the development of emulsion, lipo-
somes, microparticles and nanoparticles based on
synthetic or natural polymers [3]. They combine the
advantages of emulsions, liposomes and polymeric nano-
particles. The solid matrix can protect incorporated active
ingredients against chemical degradation and provide the
highest flexibilities in the modulation of the drug release
profiles. Moreover, the SLNs are composed of physiologi-
cally well tolerated excipients. Advantages of SLN and
NLC include a potentially wide application spectrum
(dermal, oral, intravenous), the use of biodegradable
physiological lipids or lipidic stabilizers which are gener-
ally recognized as safe (GRAS) or have a regulatory
accepted status. NLC composed of solid lipid matrix with
certain content of liquid lipid are a new generation of
lipid nanoparticles. The incorporation of liquid lipids
into solid lipid matrix leads to great imperfections in the
crystal lattice of nanoparticles, thus leading to improved
drug loading capacity and reduced drug expulsion during
storage [4,5].
As transdermal delivery system, SLN and NLC possess
many obvious advantages. It is assumed that SLN and
NLC, when administered directly onto skin in a small but
sufficient quantity, would cause less side effects, if any,
than the currently available formulations. SLN and NLC
seem to be well suited for use on damaged or inflamed
skin because they are based on non-irritative and non-
toxic lipids. With respect to their use as carriers for topical
applications, the occlusive effect due to film formation on
the skin surface that reduces transepidermal water loss
(TEWL). Increasing the water content in the skin can
reduce the symptoms of atopic eczema and improve the
appearance of healthy human skin. Occlusion can also
enhance the penetration of drugs through the stratum cor-
neum by increased hydration. Apart from a nonspecific
occlusion effect on penetration, penetration might also be
affected by the SLN and NLC carrier itself, the high specific
surface area of nanometer sized SLN and NLC facilitates
contact of encapsulated drugs with the stratum corneum
[4].
The main purpose is to investigate the latest develop-
ments of innovative solid lipid carriers, particularly solid
lipid nanoparticles (SLN) and nanostructured lipid carri-
ers (NLC), for transdermal delivery of flurbiprofen.
Flurbiprofen is a chiral non-steroidal anti-inflammatory
drug (NSAID) of the 2-arylpropionic acid class. Flurbipro-
fen, one of the most potent inhibitors of platelet aggrega-
tion currently available, is used to treat gout,
osteoarthritis, rheumatoid arthritis, and sunburn. Flurbi-
profen has also been found to cause a dose-dependent
inhibition of collagen-induced platelet aggregation in
platelet-rich plasma from human, rats and rabbits in vitro.
Upon oral administration, the most frequently reported
side effects of flurbiprofen are abdominal discomfort
along with other gastrointestinal effects. Also, it has a
short elimination half-life of 3.9 h and requires frequent
dosing. Therefore long-term percutaneous absorption of
flurbiprofen at a controlled rate is needed. Transdermal
delivery would provide a means to avoid the gastrointes-
tinal damage associated with oral route. However, inter-
cellular lipid barrier in the stratum corneum has
formidable barrier properties and most of the drugs can-
not penetrate the skin readily.
The aims of the present study were to 1) develop SLN and
NLC enriched hydrogels for transdermal delivery, 2) per-
form in vitro and in vivo permeation studies through rat
skin, and 3) evaluate the efficacy of SLN/NLC gels against
inflammation induced rats. The purpose was to provide
the delivery of the drug at a controlled rate across intact
skin to improve bioavailability and inflammation control
for longer period from SLN/NLC gels.
This paper was also designed to assess the possibility to
develop SLN and NLC based semi-solid formulations
using a well established hydrogel as transdermal vehicle.
We have also tried to improve the bioavailability of the
transdermally applied flurbiprofen. The objectives of this
study were to develop a patient non infringing drug deliv-
ery system that could reduce the side effects due to opti-
mization of the blood concentration time profile and to
extend duration of activity which allows greater patient
compliance owing to elimination of multiple dosing
schedules.
Methods
Materials
The following materials were used from the indicated
sources without further purification procedures. Flurbi-
profen and ibuprofen were kindly gifted by Sun Pharma-
ceutical Industries LTD (Mumbai, India). Trimyristin
(TM) (Dynasan 114) was generously supplied by Sasol
(Witten, Germany); Captex 355 EP/NF (triglycerides of
caprylic and capric acid) was donated by Abitec Corpora-
tion (Janesville, Winsconsin, USA), Soy phosphatidylcho-
line 99% (Epikuron 200) was donated by DegussaLipids in Health and Disease 2009, 8:6 http://www.lipidworld.com/content/8/1/6
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Texturant Systems (Deutschland, Hamburg, Germany).
Tween 80 and dialysis membrane-70 were purchased
from Hi-Media (Mumbai, India). For hydrogel prepara-
tion, Carbopol 934 (polyacrylate) was purchased from BF
Goodrich (Cleveland, Ohio, USA), Xanthan gum was pur-
chased from Sigma-Aldrich (Mumbai, India), hydroxy
propyl cellulose (HPC) was purchased from Hi-Media
(Mumbai, India). Chitosan (degree of deacetylation,
80.8%) was gifted by Central Institute of Fisheries Tech-
nology and India Sea Foods (Kochi, India). Centrisart fil-
ters (molecular weight cutoff 20,000) were purchased
from Sartorius (Goettingen, Germany). The other chemi-
cals were of analytical reagent grade.
Preparation of aqueous SLN and NLC dispersions of 
Flurbiprofen
FLU (1% w/v), Dynasan 114 (5% w/v), and phosphatidyl-
choline 99% (2% w/v) were dissolved in 10 ml mixture of
chloroform and methanol (1:1). Organic solvents were
completely removed using a rotoevaporator (Laborota
4000, Heidolph, Germany). Drug-embedded lipid layer
was melted by heating at 58°C above melting point of the
lipid. An aqueous phase was prepared by dissolving polys-
orbate 80 (1% w/v) in double distilled water (sufficient to
produce 10 ml of preparation) and heated to same tem-
perature of oil phase. Hot aqueous phase was added to the
oil phase, and homogenization was carried out (at 12,000
rpm and temperature 70°C) using a Diax 900 homoge-
nizer (Heidolph, Germany) for 3 min. Coarse hot oil in
water emulsion so obtained was ultrasonicated (12T-
probe) using a Sonoplus ultrahomogenizer (Bandelin,
Germany) for 15 min. Flurbiprofen solid lipid nanoparti-
cles (FLUSLN) were obtained by allowing hot nanoemul-
sion to cool to room temperature.
Flurbiprofen nano-structured lipid carriers (FLUNLC)
were prepared in exactly the same manner as the SLN dis-
persions, only partially replacing 30% of the solid lipid
matrix by Captex 355 EP/NF (caprylic/capric triglycer-
ides).
Gels enriched with lipid nanoparticles
Gels were prepared using four polymers namely carbopol
934 (1%), xanthan gum (1%), hydroxyl propyl cellulose
(2%) and chitosan (1%). For the preparation of hydrogel,
the gel forming polymer was dispersed in double distilled
water containing glycerol (10%). Aqueous FLUSLN and
FLUNLC dispersions and hydrogels were mixed in a high
speed stirrer (Remi, Mumbai, India) at approximately
1000 rpm for 5 min to yield gels containing a final con-
centration of 5% lipid nanoparticles. The hydrogels com-
posed of carbopol 934 and chitosan were adjusted to pH
6.5 and 4.0 respectively. The SLN and NLC dispersions
were used as reference. The SLN and NLC loaded FLU
hydrogels were stored at room temperature for 90 days.
Physicochemical Properties of SLN and NLC Hydrogels
The SLN and NLC enriched hydrogels were characterized
for their physicochemical properties such as colour, odour
and pH.
Measurement of Particle size of SLN and NLC enriched 
hydrogels
The mean size and polydispersity index of the size distri-
bution of FLUSLN and FLUNLC was determined by pho-
ton correlation spectroscopy using Zetasizer 3000 HSA
(Malvern Instruments, Malvern, UK). The SLN dispersions
were diluted 1:1000 with the aqueous phase of the formu-
lation to get a suitable kilo counts per second (kcps).
Analysis was performed at 25°C with an angle of detec-
tion of 90°. Each value reported is the average of three
measurements. The polydispersity index measures the size
distribution of the nanoparticle population.
Measurement of zeta potential of SLN and NLC enriched 
hydrogels
Zeta potential of different formulations of flurbiprofen
SLN and NLC were measured by Photon Correlation Spec-
troscopy (PCS) using Zetasizer 3000 HSA (Malvern Instru-
ments, Malvern, UK). The SLN dispersions were diluted as
mentioned in size determination.
Assay and Entrapment Efficiency
The prepared FLUSLN/FLUNLC dispersions (0.2 ml) were
diluted to 10 ml with chloroform/methanol (1:1). Final
dilution was made with mobile phase, and FLU content
was determined by HPLC.
The entrapment efficiency of the system was determined
by measuring the concentration of free drug in the disper-
sion medium/aqueous phase of undiluted FLU/SLN dis-
persion. Ultracentrifugation was carried out using
Centrisart, which consists of filter membrane (molecular
weight cut-off, 20,000 Da) at the base of the sample recov-
ery chamber. About 1 ml of undiluted sample of FLUSLN/
FLUNLC dispersion was placed in the outer chamber, and
the sample recovery chamber was placed on top of the
sample. The unit was centrifuged at 10,000 rpm for 30
min. The SLN/NLC along with encapsulated drug
remained in the outer chamber, and aqueous phase
moved into the sample recovery chamber through filter
membrane. The amount of the FLU in the aqueous phase
was estimated by HPLC.
HPLC analysis of Flurbiprofen
The mobile phase consisted of a 40% aqueous phase
adjusted to pH 2.6 with acetic acid; and 60% acetonitrile.
Mobile phase was degassed with the help of bath sonica-
tor. The chromatographic system consisted of a Shimadzu
LC-10AT solvent delivery pump equipped with a 20 μl
loop and rheodyne sample injector. Phenomenex (25 cmLipids in Health and Disease 2009, 8:6 http://www.lipidworld.com/content/8/1/6
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× 4.6 mm ID) analytical column was used. Detector used
was SPD-10A VP dual wavelength UV-Visible detector
(Shimadzu) and the eluate was monitored at 245 nm. The
sensitivity was set at 0.001 AUFS. Flow rate was kept at 1
ml/min. The data was recorded using Winchrome Soft-
ware.
DSC Analysis
DSC analysis of flurbiprofen (FLU), trimyristin (TM),
physical mixture (PM), and lyophilized FLUSLN and
FLUNLC were performed using Perkin-Elmer DSC-7
model. The instrument was calibrated with indium. All
the samples (≈5 mg) were heated in aluminum pans using
dry nitrogen as the effluent gas. The analysis was per-
formed with a heating range of 20–200°C and at a rate of
20°C/min.
High Resolution Transmission Electron Microscopy 
(HRTEM)
Bright-field transmission electronic images were taken
using JEOL, JSM-3010 HRTEM, Japan, operated at 300
keV. Samples for TEM measurements were prepared by
dropping the dispersion of the nanoparticles on a copper
grid supported Formvar Films.
In vitro Release Studies of Flurbiprofen SLN and NLC
In vitro release studies were performed using modified
Franz diffusion cell. Dialysis membrane (purchased from
Hi-Media, Mumbai, India) having pore size 2.4 nm,
molecular weight cut-off between 12,000–14,000 was
used. Membrane was soaked in double distilled water for
12 h before mounting in a Franz diffusion cell. Phosphate
buffer pH 5.6 containing 0.5% w/v of polysorbate 80 was
used as release media. SLN/NLC dispersion (1 ml) was
placed in the donor compartment and the receptor com-
partment was filled with 0.5% polysorbate 80 in phos-
phate buffer, pH 5.6 (12 ml). During the experiments, the
solution in receptor side was maintained at 37°C ± 0.5°C
and stirred at 800 rpm with Teflon-coated magnetic stir-
ring bars. At fixed time intervals, 100 μl of the sample was
withdrawn from receiver compartment through side tube
and analyzed by HPLC.
Data obtained from in vitro release studies were fitted to
various kinetic equations to find out the mechanism of
flurbiprofen release from FLUSLN and FLUNLC [6,7]. The
kinetic models used were zero order equation, first order
equation, Higuchi release and Korsemeyer-Peppas.
Skin membrane preparation
The abdominal hair of Wister male rats, weighing 160 ±
25 g, was shaved using razors 24 h before treatment. After
anesthetizing the rat with ether, the abdominal skin was
surgically removed from the animal, and adhering subcu-
taneous fat was carefully cleaned. To remove extraneous
debris and leachable enzymes, the dermal side of the skin
was in contact with a saline solution for 1 h before starting
the diffusion experiment. All surgical and experimental
procedures were reviewed and approved by the animal
and ethics review committee of Faculty of Pharmaceutical
Sciences, Kakatiya University, Warangal, Andhra Pradesh,
India.
Ex Vivo Permeation studies
A system employing improved Franz diffusion cells with a
diffusional area of 3.56 cm2 was used for permeation stud-
ies. The excised rat skin was set in place with the stratum
corneum facing the donor compartment and the dermis
facing the receptor compartment. Two ml of SLN/NLC
dispersion/0.5 g of the gel of flurbiprofen were applied to
the skin surface in the donor compartment and the recep-
tor compartment of the cell was filled with 12 ml of saline
phosphate buffer (pH 7.4). During the experiments, the
solution in receptor side was maintained at 37 ± 0.5°C
and stirred at 800 rpm with Teflon-coated magnetic stir-
ring bars. After application of the test formulation on the
donor side, 100 μl aliquots were collected from the recep-
tor side at designated time intervals (1, 2, 4, 8, 12, 18 and
24 h). Thereafter, an equivalent volume of receptor fluid
was supplied to the receiver compartment immediately
after each sample collection. At the end of 24 h, the
amount of drug remaining on the skin and the drug con-
centration in the skin was determined by extraction into a
suitable solvent followed by HPLC analysis.
Rheological Measurements
The rheological measurements were performed on a rhe-
ometer Brookfield Programmable Rheometer LVDV-III +
CP 230 equipped with a cone and plate test geometry
(plate diameter 20 mm, cone angle 4°). All measurements
were carried out at a temperature of 20 ± 0.1°C. The rhe-
ological properties of the developed hydrogels containing
SLN and NLC were studied by continuous shear investiga-
tions, which were performed in order to evaluate the shear
rate [1/s] as a function of shear stress [Pa]. This study
started applying 0 Pa up to a maximum shear stress of 50
Pa and the resulting shear rate was measured.
In vivo Studies
The animals used for in vivo experiments were adult male
Wistar albino rats (230–250 g) procured from the central
animal house of University college of Pharmaceutical Sci-
ences, Kakatiya University, Warangal, Andhra Pradesh,
India. The animals were kept under standard laboratory
conditions, at 25 ± 1-C and 55 ± 5% relative humidity
with a 12 h light/dark cycle. The animals were housed in
polypropylene cages, with free access to a standard labo-
ratory diet (Lipton Feed, Mumbai, India) and water. The
study was approved by the Institutional Animal and Eth-
ics Committee (Faculty of Pharmaceutical Sciences,Lipids in Health and Disease 2009, 8:6 http://www.lipidworld.com/content/8/1/6
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Kakatiya University, Warangal, Andhra Pradesh, India).
Guidelines of the institutional animal ethics committee
were followed for in vivo experiments.
Pharmacokinetic Studies of SLN and NLC enriched 
Hydrogels on Animals
The protocol for the studies was approved by institutional
animal ethical committee. Wistar albino rats were used as
the animal models for the bioavailability studies. The ani-
mals were selected after superficial examination of the
skin surface for abnormalities. Only rats weighing
between 230 and 250 g were selected for the study. About
9 cm2 of skin was shaved on the dorsal side. Before appli-
cation of the gels, rats were kept under observation for 24
h for any untoward effects of shaving; they were fasted
over this period. The rats were divided into 3 groups (n =
6). Group I was administered flurbiprofen orally 10 mg/
kg, 0.5 ml suspension in 0.5% sodium carboxymethyl cel-
lulose solution in water, group II received SLN enriched
hydrogel (A1), and group III received NLC enriched
hydrogel (B1). The blood samples (250 μl) were collected
in eppendorf tubes containing EDTA drawn from the tail
vein of the rat at different time intervals (1, 2, 3, 4, 8, 12,
and 24 h). Plasma samples were separated by centrifuga-
tion at 3000 rpm for 5 min (Micro Centrifuge, Kunchun,
Korea) and stored in vials at -20°C until they were ana-
lyzed by HPLC. The results were compared with the orally
administered flurbiprofen.
Pharmacokinetic Analysis
Plasma concentration versus time data for flurbiprofen in
individual rats was analyzed by using Kinetica (version
1.1). The statistical significance of the differences between
the formulations was analyzed by Student t test using
Graph Pad InStat 3 software. A difference below the prob-
ability level of 0.05 was considered statistically significant.
Pharmacokinetic parameters Cmax, Tmax, t1/2, AUC0–24 and
AUC0-∞ were estimated. The pharmacokinetic parameters
estimated for each rat individually and average of six val-
ues was calculated.
Pharmacodynamic Studies
Carrageenan induced paw edema method was used to
study the in vivo performance of the prepared drug deliv-
ery system, and the study was approved by University Ani-
mal Ethical Committee. Anti-inflammatory activity was
determined by measuring change in the volume of
inflamed paw, produced by injection of carageenan (0.1
ml of 1% w/v) using plethysmometer (INCO, India).
Male albino rats (Wistar strain) selected for the study were
weighed and marks were made on the right hind paw just
behind tibia-tarsal junction on each animal. Thus, every
time the paw was dipped in the plethysmograph (mercury
displacement method) up to the fixed mark to ensure con-
stant paw volume. Wistar rats were divided into four
groups including one controlled group with each group
comprising of 6 animals. The paw volume was noted at 0,
1, 2, 4, 6, 8, 12 and 24 h.
The formulations A1 and B1 were applied transdermally
to albino rats of respective groups, excluding the animals
of controlled group. The controlled group animals were
injected with saline (0.9% NaCl) containing no drug.
After 30 min of transdermal application of A1 and B1 for-
mulations, 0.1 ml of 1% w/v carrageenan (in 0.9% nor-
mal saline) was injected in the sub planter region of the
right hind paw of rats. The initial reading just after injec-
tion and subsequent paw volumes was measured up to 24
h. The percent inhibition of edema induced by carra-
geenan was calculated for each group using the following
equation:
where, Vcontrol = mean oedema volume of rats in control-
led group and Vtreated = edema volume of each rat in test
group.
Results and Discussion
Characterization of the investigated formulation
For the production of aqueous FLUSLN and FLUNLC dis-
persions containing 20% of lipid matrix, the formulations
given in table 1 were chosen.
For the present investigation, four different hydrogels
were prepared using optimal stabilizer combination of
water, gel forming polymer and glycerol as hydrating
agent. The aqueous FLUSLN and FLUNLC dispersions
were admixed to the freshly prepared hydrogels. The final
composition of the investigated FLUSLN and FLUNLC
containing hydrogels were shown in table 2.
Physicochemical properties
The FLUSLN and FLUNLC dispersions were light yellow-
ish in colour, odourless and fluid in nature. It was stable
%        
inhibition of edema
Vcontrol Vtreated
Vcontrol
=
−
×100
Table 1: Composition of the investigated FLUSLN and FLUNLC formulations (% w/w)
Formulations Flurbiprofen Dynasan 114 Epikuron 200 Captex 355 Polysorbate 80
A (FLUSLN) 1.0 10 2 - 2.5
B (FLUNLC) 1.0 7 2 3 2.5Lipids in Health and Disease 2009, 8:6 http://www.lipidworld.com/content/8/1/6
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and did not show sedimentation even after centrifugation.
Gels loaded with FLUSLN and FLUNLC dispersions were
light yellow in colour, odourless with smooth appearance.
Particle size analysis
The particle sizes of lipid nanoparticles before and after
incorporation into four different hydrogels were shown in
figures 1 and 2. The P.I for Xanthan gum was approxi-
mately 0.3–0.4 and for chitosan hydrogel the P.I was
approximately 0.4. After analysis the formulations were
stored at room temperature for 90 days. For all the tested
formulations more than 50% of the particles were below
250 nm after 90 days of storage at room temperature. The
incorporation into hydrogels did not result in particle
aggregation.
Zeta potential (ζ)
FLUSLN and FLUNLC were negatively charged when
incorporated into carbopol 934, xanthan gum and HPC
hydrogels. The opposite was observed when incorporated
into chitosan hydrogels. These results are due to the cati-
onic character of the bioadhesive polymer. For carbopol
934 hydrogels, the carboxylic groups have to be neutral-
ized with sodium hydroxide in order to exhibit gel form-
ing properties. This neutralizing agent could enhance
aggregation because of the action of sodium ions as elec-
trolyte, which can reduce the ζ values of the particles [8].
As a consequence of this lower ζ value aggregation may
occur. This phenomenon is well known for lipid nano
emulsions as well as for SLN when incorporated into
polyacrylate hydrogels [9]. The ζ values of the aqueous
FLUSLN and FLUNLC dispersions before and after their
incorporation into hydrogels measured on day 1 and after
90 days of storage at room temperature are given in table
Table 2: Final composition of the investigated A (FLUSLN) and B (FLUNLC) enriched hydrogel formulations [% w/w]
Formulations Flurbiprofen Dynasan 114 Captex 355 Epikuron 200 Polysorbate 80 Gel forming agent Glycerol
A1 1 10 - 2 2.5 1% Carbopol 934 5
A2 1 10 - 2 2.5 1% Xanthan gum 5
A3 1 10 - 2 2.5 2% HPC 5
A4 1 10 - 2 2.5 1% Chitosan 5
B1 1 7 3 2 2.5 1% Carbopol 934 5
B2 1 7 3 2 2.5 1% Xanthan gum 5
B3 1 7 3 2 2.5 2% HPC 5
B4 1 7 3 2 2.5 1% Chitosan 5
Particle size analysis of FLUSLN and FLUNLC formulations after day 1 of storage at room temperature Mean, S.D (n = 3) Figure 1
Particle size analysis of FLUSLN and FLUNLC formulations after day 1 of storage at room temperature Mean, 
S.D (n = 3).Lipids in Health and Disease 2009, 8:6 http://www.lipidworld.com/content/8/1/6
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3. During storage time, the ζ value of the surface lipid nan-
oparticles remains practically unchanged (e.g. B2, A1, and
B1) or slightly decreased (e.g. A2, A3). In comparison to
FLUSLN formulations with same liquid content, FLUNLC
formulations show lower ζ values. FLUSLN and FLUNLC
aqueous dispersions can be incorporated into hydrogels
consisting of more or less uncharged polymers without
significant changes in the particle size characteristics and
ζ values [4]. In case of gel forming polymers with very
polar groups like chitosan, possible interactions between
negative surface charge of the lipid nanoparticles and
polar groups of this polymer must be taken into account.
Assay and Entrapment Efficiency
A high amount of flurbiprofen could be incorporated in
the SLN and NLC dispersions. As high as 30% of the drug
with respect to the lipid could be incorporated, such high
incorporation is possible because of the lipophilic charac-
ter of flurbiprofen. Assay results showed that concentra-
tion of flurbiprofen in the total system ranged from 0.92
to 0.99 mg/ml.
The percentage of incorporated drug in the lipid matrix
(entrapment efficiency) was evaluated over a period of 90
days. Incorporation of flurbiprofen led to high entrap-
ment efficiency, probably because of their lipophilic char-
acter. FLUNLC is responsible for higher entrapment
efficiency in comparison to FLUSLN formulation. This
result is due to the binary mixture of liquid and solid lip-
ids, resulting in only a very weak crystallization [10,11].
For all the tested formulations the entrapment efficiency
was higher than 90%.
Differential Scanning Calorimetry (DSC)
Figures 3 and 4 shows DSC curves of flurbiprofen (FLU),
trimyristin (TM), physical mixture (PM), lyophilized
FLUSLN and lyophilized FLUNLC respectively. The ther-
Particle size analysis of FLUSLN and FLUNLC formulations after day 90 of storage at room temperature Mean, S.D (n = 3) Figure 2
Particle size analysis of FLUSLN and FLUNLC formulations after day 90 of storage at room temperature 
Mean, S.D (n = 3).
Table 3: Zeta potential and SD values of FLUSLN and FLUNLC 
before and after their incorporation into hydrogels measured on 
day 1 and day 90 of storage at room temperature
Formation Day 1 Day 90
ζ S.D ζ S.D
A (FLUSLN) -28.3 3.65 -25.7 3.67
A1 -21.2 2.58 -20.2 6.54
A2 -34.2 6.53 -24.7 6.76
A3 -19.7 3.72 -15.4 4.74
A4 42.6 8.63 36.8 8.02
B(FLUNLC) -21.7 3.98 -20.5 4.99
B1 -18.9 4.11 -18.6 6.34
B2 -20.5 5.65 -19.4 7.21
B3 -16.6 4.23 -14.6 3.89
B4 40.9 7.48 32.3 8.21
A (FLUSLN) and B (FLUNLC) before incorporation into hydrogelsLipids in Health and Disease 2009, 8:6 http://www.lipidworld.com/content/8/1/6
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mograms of the lyophilized FLUSLN and FLUNLC did not
show the melting peak for the flurbiprofen around
117°C. This shows that flurbiprofen was not in crystalline
state but it is in amorphous state. Endothermic peak of
glucose used as cryoprotectant was observed at 148.5°C
in FLUSLN and FLUNLC curve. Similar results were
reported by Cavalli et al. 1997, stating that rapid quench-
ing of the microemulsion does not allow the drug to crys-
tallize [12]. DSC analysis of camptothecin SLN prepared
by high pressure homogenization showed that camp-
tothecin was in amorphous state [13]. In our method, lip-
ids and flurbiprofen were dissolved in a mixture of
solvents and subsequently, solvents were evaporated. This
allowed homogeneous dispersion of drug in the lipid.
Furthermore, method of preparation (homogenization
followed by ultrasonication) and the presence of sur-
factants do not allow the drug to crystallize. Thermody-
namic stability of lipid nanoparticles depends upon their
existing lipid modification. Polymorphic transitions after
crystallization of triglyceride nanoparticles are slower for
longer chain triglycerides than for shorter chain triglycer-
ides, whereas these transitions are faster for small size of
crystallites. The type of surfactant and storage time affects
the crystallinity of SLN/NLC and, consequently, degrada-
tion velocity [14]. Melting points of lyophilized SLN and
NLC were found to be 56.25°C and 57.25°C respectively.
High Resolution Transmission Electron Microscopy 
(HRTEM)
TEM analysis has been performed to evaluate the poten-
tial differences in particle shape and morphology of SLN
and NLC formulations. By this analysis the absence of
aggregation phenomena of trimyristin based SLN and
NLC has also been confirmed immediately after produc-
tion, and also by monitoring the particle growth during
storage time at room temperature. The TEM image of the
FLUSLN and FLUNLC were shown in figure 5 and 6
respectively. Both the figures show that the particle diam-
eters vary from about 150 to 300 nm. Both SLN and NLC
DSC thermograms of flurbiprofen (A), trimyristin (B), physi- cal mixture of flurbiprofen and trimyristin (C) and lyophilized  flurbiprofen SLN (D) Figure 3
DSC thermograms of flurbiprofen (A), trimyristin 
(B), physical mixture of flurbiprofen and trimyristin 
(C) and lyophilized flurbiprofen SLN (D).
DSC thermograms of flurbiprofen (A), trimyristin (B), physi- cal mixture of flurbiprofen and trimyristin (C) lyophilized  flurbiprofen NLC (D) and captex 355 (E) Figure 4
DSC thermograms of flurbiprofen (A), trimyristin 
(B), physical mixture of flurbiprofen and trimyristin 
(C) lyophilized flurbiprofen NLC (D) and captex 355 
(E).
TEM image of flurbiprofen solid lipid nanoparticles (FLUSLN) Figure 5
TEM image of flurbiprofen solid lipid nanoparticles 
(FLUSLN).Lipids in Health and Disease 2009, 8:6 http://www.lipidworld.com/content/8/1/6
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were investigated, no significant difference in the diame-
ter was obtained. TEM analysis suggested that immedi-
ately after production SLN and NLC formulations
contained no particles higher than 1 μm.
In vitro Release Studies
The cumulative percentage release of flurbiprofen from A
(FLUSLN) and B (FLUNLC) dispersions were investigated
for a period of 24 h; each sample was analyzed in tripli-
cate. Figure 7 shows the in vitro release profile of A
(FLUSLN) and B (FLUNLC) dispersions. A (FLUSLN)
could prolong or retard the drug release by the fact that
the drug molecules are entrapped in the solid lipid matrix.
FLUNLC, the liquid lipid enriched shell possessed soft
and considerable higher solubility for lipophilic drugs
character, in which the drug was easily loaded to higher
amount and the drug could be easily released as well by
the drug diffusion or the matrix erosion manners [15].
Furthermore, the incorporation of liquid lipid into solid
lipid matrix caused the FLUNLC become more imperfect
and allowed the loaded drug to easy release, thus
increased the drug release rate when liquid lipid was
included in NLC matrix. The results of sustained release
and increased drug release rate were achieved compared
to FLUSLN. Comparing the drug release from FLUSLN
and FLUNLC dispersions and FLUSLN and FLUNLC in
gels (figures 8 and 9), the release of FLU was slower from
gel formulation. The percentage drug release at the end of
24 h in A1 (FLUSLN) and B1 (FLUNLC) gel formulations
was found to 54.87% and 64.45% respectively whereas
the percentage drug release at the end of 24 h in A
(FLUSLN) and B (FLUNLC) dispersions was 63.66% and
72.65% respectively. Incorporation of SLN and NLC dis-
persion into gels decreased the drug release; this may be
due to the release retarding effect of the polymeric matrix
of the gelling agent.
TEM image of flurbiprofen nanostructured lipid carrier  (FLUNLC) Figure 6
TEM image of flurbiprofen nanostructured lipid car-
rier (FLUNLC).
In vitro release profile of FLU in SLN and NLC dispersions, Mean S.D (n = 3) Figure 7
In vitro release profile of FLU in SLN and NLC dispersions, Mean S.D (n = 3)Lipids in Health and Disease 2009, 8:6 http://www.lipidworld.com/content/8/1/6
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A different release kinetic was observed for the SLN disper-
sions and SLN gel formulations. Fick's law of diffusion
seems not to be applicable in each case. An initial rapid
drug release was noted in the SLN/NLC dispersions,
whereas a lag time was observed with SLN/NLC enriched
gel formulations which could result from the time taken
by the drug to diffuse across the gel. The direct exposure of
SLN/NLC dispersion to diffusion media and quick release
of drug may account for rapid initial release in SLN/NLC
dispersions. Both SLN/NLC dispersions and SLN/NLC
enriched gel formulations showed controlled drug release
and also an increase in release rate was observed after 24
h.
The log percent cumulative drug released was plotted as a
function of log time and the slope of the curves was deter-
In vitro release of FLU from gels enriched with SLN dispersion, Mean S.D (n = 3) Figure 8
In vitro release of FLU from gels enriched with SLN dispersion, Mean S.D (n = 3)
In vitro release of FLU from gels enriched with NLC dispersions, Mean S.D (n = 3) Figure 9
In vitro release of FLU from gels enriched with NLC dispersions, Mean S.D (n = 3)Lipids in Health and Disease 2009, 8:6 http://www.lipidworld.com/content/8/1/6
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mined as the values of diffusional release exponent (η).
The values of diffusional release exponent (η) from the
straight lines were noted to be 0.69–0.82 in SLN disper-
sions and SLN gel formulations, which showed that the
release of drug from formulations followed a non-Fickian
pattern [16]. From the percent cumulative drug released
versus time plot, the slope values were determined as
release rate constants. The percent cumulative drug
released for B (FLUNLC) 72.65% and A (FLUSLN)
63.66% with release rate constants of 2.9515 and
2.691%/cm2/h, respectively. B1 (NLC) (63.45%) and A1
(SLN) gel (54.85%) have minimum drug release with
release rate constants of 2.7527 and 2.4488%/cm2/h,
respectively. A1 and B1 gel slowly releases the drug as
compared with SLN and NLC dispersion, accounted for by
the time the drug takes to diffuse through gel. The slower
release of drug from SLN and NLC enriched carbopol gel
maintained the drug concentration for longer period of
time. Burst releases as well as sustained release both are of
interest for dermal application. Burst release can be useful
to improve the penetration of drug. Sustained release sup-
plied the drug over a prolonged period of time.
In vitro Skin permeation studies
The in vitro skin permeation of flurbiprofen SLN and NLC
was investigated through rat skin using Franz diffusion
cell were shown in figure 10. B1 formulation hydrogel
(area of 3.56 cm2) exhibited the greatest (3792.54 ±
149.98 μg/cm2) cumulative amount of drug permeation
in 24 h than A1 formulation. The release kinetics was
established by determining the diffusional release expo-
nent from the plot of log of cumulative drug permeated
versus log time. This plot yielded a straight line from
which diffusional release exponent (n) was calculated and
found to be between 0.89 – 0.96 for both SLN/NLC dis-
persions and SLN/NLC carbopol gel formulations, which
showed that the release of drug from these formulations
followed a non-Fickian pattern [16,17]. A lag time (15–30
min) was observed in every case but more in SLN/NLC gel
formulations because in these formulations the drug has
to cross two diffusion barriers, one the gel and the other is
skin. The SLN/NLC dispersions and SLN/NLC enriched
gel formulations possessed a sustained drug release over a
period of 24 h period. But this sustained effect was more
pronounced with SLN/NLC enriched gel formulations
when compared to SLN/NLC dispersions.
From the percent cumulative drug permeated versus time
plot, the slope values were determined as the skin perme-
ation rate. The cumulative amount of drug permeated at
the end of 24 h was found to be 3671.76 ± 128.82 and
4578.89 ± 116.16 μg/cm2 with skin permeation rate con-
Ex vivo permeation of flurbiprofen from SLN and NLC enriched hydrogels through rat abdominal skin, Mean S.D (n = 3) Figure 10
Ex vivo permeation of flurbiprofen from SLN and NLC enriched hydrogels through rat abdominal skin, Mean 
S.D (n = 3)Lipids in Health and Disease 2009, 8:6 http://www.lipidworld.com/content/8/1/6
Page 12 of 15
(page number not for citation purposes)
stants of 7.8651 and 9.7519 percent/cm2/h for A
(FLUSLN) and B (FLUNLC) dispersions respectively. The
cumulative amount of drug permeated at the end of 24 h
was found to be 3019.27 ± 126.19 and 3792.54 ± 149.98
μg/cm2 with skin permeation rate constants of 5.9897 and
7.7954 percent/cm2/h for A1 and B1 enriched carbopol
gels respectively. SLN and NLC enriched carbopol gels
released drug slowly when compared with SLN and NLC
dispersions, accounted for by the time drug takes to dif-
fuse through the gel. The slower release of drug from SLN
and NLC carbopol gels maintained the drug concentra-
tion for longer period of time.
The SLN/NLC dispersions and SLN/NLC gel formulations
possessed a sustained drug release over a period of 24 h,
but the sustained effect was more pronounced with SLN
and NLC enriched gel formulations.
The results of drug permeation from all the formulations
through the rat abdominal skin confirmed that flurbipro-
fen was released and permeated through the rat skin and
hence could possibly permeate through the human skin.
Rheological Measurements
Rheological measurements are useful for the characteriza-
tion of the viscoelastic properties of aqueous SLN and
NLC dispersions and SLN and NLC containing hydrogels.
Therefore continuous shear investigations were per-
formed in the tested hydrogel formulations in order to
evaluate the shear rate as a function of shear stress. Con-
ventional SLN and NLC aqueous dispersions contain
about 10–20% (w/w) of lipid matrix and 80–90% (w/w)
of water. As a result, liquid solid lipid dispersions possess
a low viscosity (approximately 100 mPa s) and a yield
value of practically zero. Therefore, the liquid solid lipid
dispersions usually have to be incorporated in convenient
topical dosage forms like hydrogels or creams to obtain a
topical application form having the desired semisolid
consistency [18,19].
Rheological status is a very important physical parameter
in the development of a potential new drug delivery sys-
tem for topical use. The rheological behaviour of hydro-
gels loaded with SLN and NLC was evaluated after 1 week
of storage at room temperature. The flow curves of the gels
are shown in figure 11.
Pharmacokinetic Studies of SLN and NLC enriched 
Hydrogels on Animals
Transdermal gels of 9 cm2 area, containing 1 mg of the
drug, were applied on the dorsal side of the rats. Figure 12
shows the plasma flurbiprofen concentration versus time
profiles following the application of the hydrogel formu-
lation. The time to reach maximum was 8 h for both A1
and B1 formulations. The Cmax of the B1 formulation, was
38.67 ± 2.77 μg/ml, which was significantly (P < 0.01)
higher than the A1 formulation (Cmax = 21.79 ± 2.96 mg/
ml). The Cmax and AUC of the B1 formulation were 1.8
and 2.5 times higher than the A1 formulation respectively
(Table 4).
The AUC decreased in the following order A1 > B1 > oral.
The pharmacokinetic parameters of flurbiprofen after the
oral administration were significantly different from the
parameters obtained after the transdermal application of
gel formulations. After the oral administration of flurbi-
profen, the Cmax of the drug reached within 1 h, and a
sharp decline was observed as shown in figure 12.
The increase in the AUC0–∞ of flurbiprofen after applica-
tion of transdermal gel formulations was significantly
higher than orally administered flurbiprofen, which indi-
cates the improved bioavailability of flurbiprofen through
transdermal drug delivery route. The bioavailability of
flurbiprofen with reference to orally administered flurbi-
profen was found to increase by 4.4 times when transder-
mal gel formulations were applied. Greater flurbiprofen
plasma levels were achieved immediately and were main-
tained till the last sample. In other previously reported
study flurbiprofen levels of 43.9 μg/ml were achieved in
rats at 1.8 h after the application of 500 μl of 1% flurbi-
profen containing 5% of oleic acid and 5% urea in propyl-
ene glycol, on the dorsal area of 9 cm2 [20]. In this study,
higher plasma levels of flurbiprofen were achieved with
the application of transdermal hydrogels.
Pharmacodynamic Studies
The in vivo performance of selected A1 (FLUSLN) and B1
(FLUNLC) enriched hydrogel were carried out in carra-
geenan-induced rat paw edema model. Both the formula-
tions A1 and B1 under study not only decreased the
inflammation to the larger magnitude, but also sustained
this magnitude. In A1 formulation the maximum inhibi-
tion was observed at 8th h with higher value (78.2%), up
to 8 h inhibition was maintained above 60%, and even
after 24 h, 35% inhibition was observed.
In B1 formulation maximum inhibition was observed at
8th h with higher value (86.6%), above 70% inhibition
was observed up to 8 h and more than 45% inhibition was
observed even after 24 h. However, in case oral adminis-
tration, inhibition was displayed at 1 h with magnitude of
84.6% and just after 4 h it scored below 40% (Figure 13).
The possible reason could be the drug concentration in
the blood, which was maintained for longer duration in
case of formulations A1 and B1 in comparison to the drug
administered orally. In comparison to orally administered
flurbiprofen, the two formulations A1 and B1 which were
applied transdermally gave good results. The maximum
inhibition for A1 and B1 were observed at 8 h and theLipids in Health and Disease 2009, 8:6 http://www.lipidworld.com/content/8/1/6
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inhibition was maintained up to 12 h and also even after
24 h inhibition was observed. The anti-inflammatory
activity of both the formulations (A1 and B1) was main-
tained for longer period of time due to slow release of the
drug. This was attributed to gel structure and the surface-
active properties of the gel.
Conclusion
Both FLUSLN and FLUNLC represent a highly effective,
non-irritant carrier for transdermal/topical preparations,
where improved drug penetration is desired. Improved
skin penetration can be due to enhanced contact of the
active agent and skin resulting from the large particle sur-
face area and film formation. After 90 days of storage at
different temperatures the mean diameters of SLN and
NLC remain practically the same (< 1 μm), which empha-
sizes the physical stability of these lipid particles. FLUNLC
showed higher entrapment efficiency due to their liquid
parts. FLUNLC also showed a faster release profile in com-
parison to FLUSLN. Both the SLN and NLC dispersions
and gels enriched with SLN and NLC possessed a sus-
tained drug release over period of 24 h but the sustained
effect was more pronounced with the SLN and NLC gel
formulations. The rheological investigations provide
information about application of semisolid formulations
and their performance on skin; these studies were con-
ducted both on SLN and NLC enriched hydrogels. These
systems are complex and their performance is dependent
on structure of the gel forming polymer used for hydrogel
preparation. Moreover, by increasing the solid lipid con-
tent of the dispersed phase an increase in elastic compo-
nent was observed.
The pharmacokinetic parameters obtained with transder-
mal gels were significantly different from those obtained
with oral flurbiprofen administration. The results indicate
that the elimination half-life of flurbiprofen was pro-
longed from oral administration to the gel formulations
in rats. This indicates that the drug remains in the body for
a longer period and has a sustained action. The signifi-
Shear rates of SLN and NLC containing hydrogels as a function of shear stress, measured after 7 days of storage at room tem- perature Figure 11
Shear rates of SLN and NLC containing hydrogels as a function of shear stress, measured after 7 days of stor-
age at room temperature. (Composition of formulations: Table 2)Lipids in Health and Disease 2009, 8:6 http://www.lipidworld.com/content/8/1/6
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Plasma concentrations of flurbiprofen after oral and transdermal administration (n = 6) Figure 12
Plasma concentrations of flurbiprofen after oral and transdermal administration (n = 6)
Anti-inflammatory activity of flurbiprofen SLN and NLC enriched hydrogels after transdermal application in comparison to oral  administration in carrageenan induced rat paw oedema (n = 6) Figure 13
Anti-inflammatory activity of flurbiprofen SLN and NLC enriched hydrogels after transdermal application in 
comparison to oral administration in carrageenan induced rat paw oedema (n = 6)Publish with BioMed Central    and   every 
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cantly high AUC values observed with transdermal gels
also indicate increased bioavailability of the drug from
gels compared with oral administration. Since the admin-
istration of flurbiprofen through gels resulted in sustained
and continued drug release for 24 h, the gels were able to
control the inflammation throughout the period. The
anti-inflammatory activity of both the formulations (A1
and B1) was maintained for longer period of time due to
slow release of the drug.
Clearly, the prepared transdermal gel formulations (A1
and B1) are capable of surmounting the shortcomings of
oral administration of flurbiprofen, such as low bioavail-
ability, short half-life, and high first pass metabolism.
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